Page 18 - GTM-3-4

Global Translational Medicine Parkinson’s: From cause to cure

Res. 2020;37(3):491-507. 2024;112:3585-3601.e5.
doi: 10.1007/s12640-019-00147-2 doi: 10.1016/J.NEURON.2024.08.003
9. Mattson MP, Camandola S. NF-kappaB in neuronal 20. Alqahtani T, Deore SL, Kide AA, et al. Mitochondrial
plasticity and neurodegenerative disorders. J Clin Invest. dysfunction and oxidative stress in Alzheimer’s disease, and
2001;107(3):247-254. Parkinson’s disease, Huntington’s disease and Amyotrophic
Lateral Sclerosis - An updated review. Mitochondrion.
doi: 10.1172/JCI11916
2023;71:83-92.
10. Kim TW, Koo SY, Riessland M, et al. TNF-NF-κB-p53
axis restricts in vivo survival of hPSC-derived dopamine doi: 10.1016/J.MITO.2023.05.007
neurons. Cell. 2024;187(14):3671-3689.e23. 21. Dias V, Junn E, Mouradian MM. The role of oxidative stress
in Parkinson’s disease. J Parkinsons Dis. 2013;3(4):461-491.
doi: 10.1016/J.CELL.2024.05.030
doi: 10.3233/JPD-130230
11. Kim HJ, Kim H, Lee JH, Hwangbo C. Toll-like receptor 4
(TLR ): New insight immune and aging. Immun Ageing. 22. Jenner P. Oxidative stress in Parkinson’s disease. Ann Neurol.
4
2023;20(1):67. 2003;53(Suppl 3):S26-S36; discussion S36-S38.
doi: 10.1186/s12979-023-00383-3 doi: 10.1002/ANA.10483
12. Quan W, Liu Y, Li J, et al. Investigating the TLR /TAK /IRF 7 23. Wang BY, Ye YY, Qian C, et al. Stress increases MHC-I
1
4
axis in NLRP -mediated pyroptosis in Parkinson’s disease. expression in dopaminergic neurons and induces
3
Inflammation. 2024;47(1):404-420. autoimmune activation in Parkinson’s disease. Neural Regen
Res. 2021;16(12):2521-2527.
doi: 10.1007/S10753-023-01918-Y
doi: 10.4103/1673-5374.313057
13. Decout A, Katz JD, Venkatraman S, Ablasser A. The cGAS-
STING pathway as a therapeutic target in inflammatory 24. Keeney MT, Rocha EM, Hoffman EK, et al. LRRK2
diseases. Nat Rev Immunol. 2021;21(9):548-569. regulates production of reactive oxygen species in cell
and animal models of Parkinson’s disease. Sci Transl Med.
doi: 10.1038/S41577-021-00524-Z
2024;16(767):17-20.
14. Sliter DA, Martinez J, Hao L, et al. Parkin and PINK 1
mitigate STING-induced inflammation. Nature. 2018; doi: 10.1126/SCITRANSLMED.ADL3438
561(7722):258-262. 25. Klemmensen MM, Borrowman SH, Pearce C, Pyles B,
Chandra B. Mitochondrial dysfunction in neurodegenerative
doi: 10.1038/S41586-018-0448-9
disorders. Neurotherapeutics. 2024;21(1):e00292.
15. Zhao M, Wang B, Zhang C, et al. The DJ -Nrf -STING axis
2
1
mediates the neuroprotective effects of Withaferin A in doi: 10.1016/j.neurot.2023.10.002
Parkinson’s disease. Cell Death Differ. 2021;28(8):2517-2535. 26. Li HY, Liu DS, Zhang YB, Rong H, Zhang XJ. The interaction
between alpha-synuclein and mitochondrial dysfunction in
doi: 10.1038/S41418-021-00767-2
Parkinson’s disease. Biophys Chem. 2023;303:107122.
16. Jiang SY, Tian T, Yao H, et al. The cGAS-STING-YY axis
1
accelerates progression of neurodegeneration in a mouse doi: 10.1016/J.BPC.2023.107122
model of Parkinson’s disease via LCN -dependent astrocyte 27. Geibl FF, Henrich MT, Xie Z, et al. α-Synuclein pathology
2
senescence. Cell Death Differ. 2023;30(10):2280-2292. disrupts mitochondrial function in dopaminergic and
cholinergic neurons at-risk in Parkinson’s disease. bioRxiv
doi: 10.1038/S41418-023-01216-Y
[Preprint]. 2023.
17. Calabresi P, Di Lazzaro G, Marino G, Campanelli F,
Ghiglieri V. Advances in understanding the function of doi: 10.1101/2023.12.11.571045
alpha-synuclein: Implications for Parkinson’s disease. Brain. 28. Nguyen M, Wong YC, Ysselstein D, Severino A,
2023;146(9):3587-3597. Krainc D. Synaptic, mitochondrial, and lysosomal dysfunction
in Parkinson’s disease. Trends Neurosci. 2019;42(2):140-149.
doi: 10.1093/brain/awad150
doi: 10.1016/J.TINS.2018.11.001
18. Endo H, Ono M, Takado Y, et al. Imaging α-synuclein
pathologies in animal models and patients with Parkinson’s 29. Borsche M, Pereira SL, Klein C, Grünewald A. Mitochondria
and related diseases. Neuron. 2024;112(15):2540-2557.e8. and Parkinson’s disease: Clinical, molecular, and translational
aspects. J Parkinsons Dis. 2021;1(1):45-60.
doi: 10.1016/J.NEURON.2024.05.006
doi: 10.3233/JPD-201981
19. Xiang J, Tang J, Kang F, et al. Gut-induced alpha-Synuclein
and Tau propagation initiate Parkinson’s and Alzheimer’s 30. Jia F, Fellner A, Kumar KR. Monogenic Parkinson’s disease:
disease co-pathology and behavior impairments. Neuron. Genotype, phenotype, pathophysiology, and genetic testing.

Volume 3 Issue 4 (2024) 10 doi: 10.36922/gtm.5082